SAN CARLOS, Calif.--(BUSINESS WIRE)--Dren Bio, a privately held, clinical-stage biotechnology company developing first-in-class antibody therapeutics for cancer, autoimmune, and other serious diseases, today announced the closing of an oversubscribed $350 million private financing. The round was co-led by Juvia Group and Lightspeed Venture Partners, with participation from an expanded syndicate of new investors including Mirae Asset Capital Life Science, General Catalyst, Cormorant Asset Managem
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.